Avita Medical Names Erin Liberto as Chief Commercial Officer
August 30 2017 - 7:27PM
Business Wire
Avita Medical, Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device
company developing innovative therapeutic solutions derived from
the regenerative properties of a patient’s own skin, today
announced that Erin Liberto has become the company’s Chief
Commercial Officer effective 28 August 2017.
As CCO of Avita Medical, Ms. Liberto will have responsibility
for successful execution of the company’s comprehensive commercial
strategy including the further development of the company’s sales,
reimbursement and marketing efforts, and will report directly to
Chief Executive Officer Dr. Michael Perry.
“Erin’s extensive experience in the global dermatology markets,
including a proven track record of successful US product launches,
will be instrumental as we position ReCell® in the US burns market
following our anticipated PMA approval next year," said Dr. Perry.
"We are laying the foundation for our future growth across multiple
indications, and I’m energized to be working with Erin as we
continue to leverage our clinical progress across a broad range of
indications."
Ms. Liberto was most recently Vice President of Marketing,
Topical Dermatology at Allergan (NYSE: AGN) where she led the
commercial operations of marketing and strategic communication for
two dermatology franchises: SkinMedica®, a cash-pay, physician
dispensed topical aesthetics business unit, and the Medical
Dermatology division which included reimbursed topical
pharmaceutical products for skin conditions and where she oversaw
more than US$650M of business revenue. While at Allergan, she
doubled the domestic SkinMedica® growth rate; gained the #1 share
position for the therapeutic acne product Aczone®; launched the new
7.5% Aczone® formulation in mid-2016, and achieved the most
successful launch in the professional dispensed skin care market.
Previously, (2001-2007) Erin served as Director of US Marketing at
Biosense Webster, a division of Johnson & Johnson (NYSE:
JNJ).
ABOUT AVITA MEDICAL LIMITED
Avita’s patented and proprietary collection and application
technology provides innovative treatment solutions derived from the
regenerative properties of a patient’s own skin. Our medical
devices work by preparing a Regenerative Epithelial Suspension
(RES™), an autologous suspension comprised of the patients’
own skin cells and wound healing factors that are necessary to
regenerate natural healthy skin. This is then applied to the area
to be treated.
In all countries outside of Europe, our portfolio is marketed
under the ReCell® brand to promote skin healing in a wide
range of applications including burns, chronic wounds and
aesthetics.
ReCell® is TGA‐registered in Australia, and CFDA‐cleared in
China. In the United States, ReCell® is an investigational
device limited by federal law to investigational use.
In Europe, our portfolio of medical device products received
CE-mark approval as three tailored product presentations, with
three individual brand names. ReCell® is designed for the
treatment of burns and plastic reconstructive procedures;
ReGenerCell™ has been formulated for chronic wounds including leg
and foot ulcers; and ReNovaCell™ is tailored for aesthetic
applications including the restoration of pigmentation.
To learn more, visit www.avitamedical.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This letter includes forward-looking statements. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “intend,” “could,” “may,”
“will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,”
“target,” “project,” “continue,” “outlook,” “guidance,” “future,”
other words of similar meaning and the use of future dates.
Forward-looking statements in this letter include, but are not
limited to, statements concerning, among other things, our ongoing
clinical trials and product development activities, regulatory
approval of our products, the potential for future growth in our
business, and our ability to achieve our key strategic, operational
and financial goal. Forward-looking statements by their nature
address matters that are, to different degrees, uncertain. Each
forward-looking statement contained in this letter is subject to
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statement.
Applicable risks and uncertainties include, among others, the
timing of regulatory approvals of our products; physician
acceptance, endorsement, and use of our products; failure to
achieve the anticipated benefits from approval of our products; the
effect of regulatory actions; product liability claims; risks
associated with international operations and expansion; and other
business effects, including the effects of industry, economic or
political conditions outside of the company’s control. Investors
should not place considerable reliance on the forward-looking
statements contained in this letter. Investors are encouraged to
read our publicly available filings for a discussion of these and
other risks and uncertainties. The forward-looking statements in
this letter speak only as of the date of this release, and we
undertake no obligation to update or revise any of these
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170830006317/en/
AustraliaMonsoon CommunicationsSarah KemterPhone:
+61 (0)3 9620 3333Mobile: +61 (0)407 162
530sarahk@monsoon.com.auorUSAWestwicke PartnersJamar
IsmailPhone +1 (415) 513-1282jamar.ismail@westwicke.com
AVITA Medical (ASX:AVH)
Historical Stock Chart
From Mar 2024 to Apr 2024
AVITA Medical (ASX:AVH)
Historical Stock Chart
From Apr 2023 to Apr 2024